This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BIO CEO Conference Live Blog: Day 2

Editor's note: The person posting comments as "RJ Kirk" in Tuesday's BIO CEO Live Blog is not the chairman of Clinical Data.

NEW YORK ( TheStreet) -- Small- and midsized biotech companies get a second day in the investor spotlight this week at the 13th annual BIO CEO & Investor Conference.

I'll be continuing my live-blogging from the BIO CEO conference today, presenting news updates and analysis live from the presentation rooms and breakout (Q&A) sessions.

Biotech companies on my coverage list Tuesday include: Spherix (SPEX), SuperGen (SUPG), Clinical Data (CLDA), Cel-Sci (CVM), Aastrom Biosciences (ASTM), AVI BioPharma (AVII) and Neoprobe (NEOP).

>>BIO CEO Conference Blog, Day 1

I'll also be reporting on presentations from StemCells (STEM), YM BioSciences (YMI), Ziopharm Oncology (ZIOP - Get Report), Cell Therapeutics (CTIC - Get Report), Icagen (ICGN) and Telik (TELK).

The BIO CEO conference is sponsored by BIO, the biotech industry-lobbying group based in Washington, D.C., and typically invites small- and mid-cap biotech companies to present to an audience of institutional investors. Smaller biotech companies, in particular, lack extensive research coverage from investment banks, so this conference is a good way for these companies to get their stories in front of investors.

This BIO CEO confab live blog will be similar to the real-time coverage I provided in January of the J.P. Morgan Healthcare Conference. Expect breaks in between my postings today because I'll be moving around the conference and waiting for companies to present throughout the day.

I'll do my best to give you continuous coverage, but understand that I'm somewhat at the mercy of the AT&T network and my ability to type into my iPhone while weaving through crowds and listening to biotech executives speak.

Your best bet is to check back into the live blog several times throughout the day.

Like my previous live blogs, I want to keep today's coverage interactive, so feel free to ping me with comments and questions. I will publish and respond to as many of your comments and questions as I can.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $0.50 -1.50%
ASTM $3.10 -0.18%
ZIOP $7.61 -3.40%
AAPL $94.05 0.44%
FB $117.79 -0.66%


Chart of I:DJI
DOW 17,721.49 -169.67 -0.95%
S&P 500 2,057.74 -23.69 -1.14%
NASDAQ 4,755.5320 -62.0620 -1.29%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs